$ADM

September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio

September historically underperforms for U.S. equities, with indices like S&P 500, Dow, and Nasdaq showing average declines. This year, factors like high oil prices, rising Treasury yields, and Fed rate hike expectations add to market concerns. Zacks Investment Research recommends Archer-Daniels-Midland (ADM), Amgen (AMGN), and Sunoco LP (SUN) as defensive stocks with strong fundamentals and growth prospects.

Original reporting
Published Sep 16, 2026, 1:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio — source image
Decision brief

The 30-second read

$ADMBullishMed
01

Why it matters

Guidance upgrades for ADM, AMGN, and SUN provide fresh, material information that could drive short‑term price appreciation.

02

Market read

Guidance upgrades for three defensive stocks may attract capital amid a seasonally weak market, offering modest upside opportunities.

03

What to watch

Rising oil prices and higher Treasury yields could offset earnings benefits for these low‑beta stocks.

Relevance 6/10Novelty 6/10Timing: September 16 2026 (today)

Background

The article highlights September’s historically weak performance and recommends three low‑beta, high‑yield stocks with upgraded guidance.

Company-level read

Ticker impact

$ADMBullishHigh confidence
Context

Archer-Daniels-Midland raised its 2026 adjusted earnings guidance to $5.15‑$5.60 per share, up from $4.15‑$4.70.

Expected impact

Potential upside of 5‑10% over the next few weeks.

Evidence & confidence

Guidance lift is a primary disclosure with material dollar scale for a large cap agribusiness.

$AMGNBullishHigh confidence
Context

Amgen increased its 2026 revenue guidance to $38.2‑$39.4 bn and adjusted earnings guidance to $22.30‑$23.50 per share.

Expected impact

Possible 4‑8% rally if market digests the upgrade.

Evidence & confidence

Guidance upgrade for a mega‑cap biotech is a fresh, material fact.

$SUNBullishHigh confidence
Context

Sunoco raised its 2026 adjusted EBITDA guidance to $3.5‑$3.7 bn, up $400 m from prior range.

Expected impact

Likely 3‑6% upside in the short term.

Evidence & confidence

EBITDA guidance increase is a primary disclosure for a mid‑cap energy distributor.

Market effects

Defensive, low‑beta consumer staples and health‑care may attract capital as September historically drags equities.

U.S. equity market bias toward defensive stocks could temper broader index declines.

Guidance upgrades may influence global commodity‑linked exposure (e.g., bio‑fuel demand for ADM).

Counterpoint

September historically hurts equities; the guidance upgrades may be priced in quickly, limiting upside.

Key entities

  • Archer-Daniels-Midland Co.

    Agribusiness firm with raised 2026 earnings guidance.

  • Amgen Inc.

    Biotech with increased 2026 revenue and earnings guidance.

  • Sunoco LP

    Fuel distributor with higher 2026 EBITDA guidance.

Related articles

$AMGNHighAI 9/10

Amgen Discloses Phase 3 Sjögren’s Data Ahead of ACR Convergence 2026

Amgen (AMGN) announced plans to present Phase 3 data for dazodalibep, a potential treatment for Sjögren’s disease, at ACR Convergence 2026. The OASIZ-301 study showed statistically significant improvements in disease activity and patient-reported dryness. Amgen is also studying dazodalibep in another Phase 3 trial expected to complete in Q4 2026. There are currently no FDA-approved medicines for Sjögren’s disease.

$AMGNMed

FDA says Amgen’s video ads for Vectibix ‘false or misleading’

The FDA sent a letter to Amgen (AMGN) stating that a promotional video for Vectibix is 'false or misleading' and violates the Federal Food, Drug, and Cosmetic Act. The FDA claims the video misrepresents the drug's safety and effectiveness, omitting risk information and full FDA-approved indications. The agency demands immediate action to address these violations, warning of potential legal action if not resolved.

$AMGNMedAI 9/10

Imdelltra Plus Imfinzi Cut Death Risk 58% for Patients with Extensive-Stage Small Cell Lung Cancer in Interim Results

Amgen's Imdelltra (tarlatamab) plus AstraZeneca's Imfinzi (durvalumab) reduced death risk by 58% in extensive-stage small cell lung cancer patients, per interim phase 3 trial results. Median survival was 21.1 months vs. 12.7 months for Imfinzi alone. The combination is not yet approved for this use. Imdelltra is approved in the U.S. for later-line treatment. Side effects were more common with the combination.